Klinische Wochenschrift

, Volume 64, Issue 23, pp 1217–1221

Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate

  • H. R. Ochs
  • D. J. Greenblatt
  • A. Locniskar
  • J. Weinbrenner


The influence of propranolol coadministration or of cigarette smoking on the kinetics of desmethyldiazepam following a single 20-mg intravenous dose of clorazepate dipotassium was evaluated in healthy volunteers. In Study One, intravenous clorazepate was given once in the control condition, and again during coadministration of propranolol, 80 mg twice daily. Compliance with the prescribed propranolol regimen was verified by measurement of serum propranolol concentrations (mean, 37 ng/ml). In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound). There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h,P<0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg,P<0.02) attributable to propranolol. In Study Two, desmethyldiazepam kinetics were compared in eight cigarette smokers (mean, 19 cigarettes/day) and in 11 nonsmoking controls matched for age, sex, and body weight. There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound). Thus, propranolol slightly although significantly impairs the clearance of desmethyldiazepam and prolongs its halflife. Cigarette smoking has no apparent influence on desmethyldiazepam kinetics.

Key words

Pharmacokinetics Desmethyldiazepam Clorazepate Propranolol Smoking 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boston Collaborative Drug Surveillance Program (1973) Clinical depression of the nervous system due to diazepam and chloridazepoxide in relation to cigarette smoking and age. N Engl J Med 288:277–280Google Scholar
  2. 2.
    Breckenridge AM, Davies HC (eds) (1984) Beta-adrenoreceptor blocker/drug interactions. Br J Clin Pharmacol 17 [Suppl 1]:1s–113sGoogle Scholar
  3. 3.
    Dawson GW, Vestal RE (1982) Smoking and drug metabolism. Pharmacol Ther 15:207–221Google Scholar
  4. 4.
    Divoll M, Greenblatt DJ, Arendt RM (1983) Propranolol kinetics: use of automated liquid chromatography. Int J Clin Pharmacol 22:457–460Google Scholar
  5. 5.
    Greenblatt DJ, Franke K, Huffman DH (1978) Impairment of antipyrine clearance in humans by propranolol. Circulation 57:1161–1164Google Scholar
  6. 6.
    Greenblatt DJ, Ochs HR, Lloyd BL (1980) Entry of diazepam and its major metabolite into cerebrospinal fluid. Psychopharmacology 70:89–93Google Scholar
  7. 7.
    Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI (1983) Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 14:251–292Google Scholar
  8. 8.
    Greenblatt DJ, Shader RI, Abernethy DR (1983) Current status of benzodiazepines. N Engl J Med 309:354–358, 410–416Google Scholar
  9. 9.
    Jusko WJ (1978) Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm 6:7–39Google Scholar
  10. 10.
    Jusko WJ (1979) Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev 9:221–236Google Scholar
  11. 11.
    Moschitto LJ, Greenblatt DJ (1983) Concentration-independent plasma protein binding of benzodiazepines. J Pharm Pharmacol 35:179–180Google Scholar
  12. 12.
    Norman TR, Fulton A, Burrows GD, Maguire KP (1981) Pharmacokinetics of N-Desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. Eur J Clin Pharmacol 21:229–233Google Scholar
  13. 13.
    Ochs HR (1983) Benzodiazepine: Bedeutung der Kinetik für die Therapie. Klin Wochenschr 61:213–224Google Scholar
  14. 14.
    Ochs HR, Bodem G, Bales G, Greenblatt DJ, Smith TW (1978) Increased clearance of digoxin in rabbits during repeated administration. J Pharmacol Exp Ther 205:516–524Google Scholar
  15. 15.
    Ochs HR, Greenblatt DJ, Allen MD, Harmatz JS, Shader RI, Bodem G (1979) Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clin Pharmacol Ther 26:449–456Google Scholar
  16. 16.
    Ochs HR, Carstens G, Greenblatt DJ (1980) Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 303:373–377Google Scholar
  17. 17.
    Ochs HR, Greenblatt DJ, Otten H (1981) Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr 59:899–903Google Scholar
  18. 18.
    Ochs HR, Steinhaus E, Locniskar A, Knüchel M, Greenblatt DJ (1982) Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. Klin Wochenschr 60:411–415Google Scholar
  19. 19.
    Ochs HR, Greenblatt DJ, Verburg-Ochs B (1984) Propranolol interactions with diazepam, lorazepam, and alprazolam. Clin Pharmacol Ther 36:451–455Google Scholar
  20. 20.
    Ochs HR, Greenblatt DJ, Verburg-Ochs B, Locniskar A (1984) Comparative single-dose kinetics of oxazolam, prazepam, and clorazepate: three precursors of desmethyldiazepam. J Clin Pharmacol 24:446–451Google Scholar
  21. 21.
    Ochs HR, Greenblatt DJ, Knüchel M (1985) Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. Chest 87:223–226Google Scholar
  22. 22.
    Smith RB, Gwilt PR, Wright CE (1983) Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharm 2:139–143Google Scholar
  23. 23.
    Shader RI, Greenblatt DJ, Ciraulo DA, Divoll M, Harmatz JS, Georgotas A (1981) Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology 75:193–197Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • H. R. Ochs
    • 1
    • 2
  • D. J. Greenblatt
    • 1
    • 2
  • A. Locniskar
    • 1
    • 2
  • J. Weinbrenner
    • 1
    • 2
  1. 1.Marienkrankenhaus Soest, Medizinische UniversitätsklinikUniversität BonnBundesrepublik Deutschland
  2. 2.Division of Clinical Pharmacology, Departments of Psychiatry and MedicineTufts University School of Medicine and New England Medical Center HospitalBoston

Personalised recommendations